Evidence map›Paper›PMID 39060375›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice.

Ingrid Julienne Georgette Burvenich, Laura Danielle Osellame, Angela Rigopoulos, Nhi Huynh, Zhipeng Cao, Nicholas Johannes Hoogenraad, Andrew Mark Scott

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ingrid Julienne Georgette BurvenichTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
Laura Danielle OsellameTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
Angela RigopoulosTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
Nhi HuynhTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
Zhipeng CaoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
Nicholas Johannes HoogenraadDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3083, Australia.
Andrew Mark ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia. andrew.scott@onjcri.org.au.ORCID 0000-0002-6656-295X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [

methods[

results[

conclusionOur results demonstrate that Fn14 receptor activation is linked to glucose metabolism of cachexia-inducing tumours.

Indexed as

BrainCachexiaFluorodeoxyglucose F18GlycolysisPositron-Emission TomographyTWEAK ReceptorAnimalsAntibodies, MonoclonalCell Line, TumorMagnetic Resonance ImagingMiceMolecular Targeted TherapyAntibodies, MonoclonalFluorodeoxyglucose F18Tnfrsf12a protein, mouseTWEAK Receptor002 antibody[18F]FDG PETCancer cachexiaFn14 receptorTWEAK

Identifiers

PMID39060375
PMCPMC11527931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.